Skip to main content
Arbutus Biopharma Corp logo

Arbutus Biopharma Corp — Investor Relations & Filings

Ticker · ABUS ISIN · CA03879J1003 US Manufacturing
Open in API
Filings indexed 1,014 across all filing types
Latest filing 2023-11-07 Interim / Quarterly Rep…
Country US United States of America
Listing US ABUS

About Arbutus Biopharma Corp

https://www.arbutusbio.com/

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapeutics for viral diseases, with a primary emphasis on creating a functional cure for chronic Hepatitis B virus (cHBV) infection. The company's strategy involves developing combination regimens that utilize multiple agents with complementary mechanisms of action. This approach aims to suppress viral replication, reduce viral antigens, and reawaken the host's immune response. A key candidate in its pipeline is imdusiran, an RNA interference (RNAi) therapeutic. Arbutus leverages its expertise in virology and drug delivery systems to advance its portfolio of clinical assets for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2023
2023-11-07 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes specific items such as Item 2.02 (Results of Operations and Financial Condition) referencing a press release of financial results for the third quarter ended September 30, 2023, and Item 8.01 (Other Events) including a corporate presentation. The document itself does not contain detailed financial statements or comprehensive financial data but rather announces the release of a press release and a presentation. The document length is 3973 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, announcements of financial results or presentations without the full report content should be classified as Regulatory Filings (RNS) because Form 8-K is a regulatory filing used to disclose material events. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2023-11-07 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated November 7, 2023, reporting the retirement of the CEO and director William H. Collier and the appointment of Michael J. McElhaugh as interim CEO and director. The content focuses on changes in the company's board and senior management, including biographical details and employment agreements. There are no financial statements or earnings data presented. The primary subject is the announcement of management changes, which fits the category of Board/Management Information (MANG). The document length is 7451 characters, sufficient to contain detailed information about management changes rather than a brief announcement. Therefore, the correct classification is MANG with high confidence.
2023-11-07 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes an Item 8.01 "Other Events" describing a press release about clinical data presentations at a conference, and Item 9.01 referencing exhibits including the press release. The document is relatively short (3627 characters) and primarily serves as an announcement of an event and filing of a press release, not a detailed financial report or other specific report type. It does not contain financial statements, management discussion, or detailed data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2023-10-11 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-09-11 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes an announcement of pipeline updates, discontinuation of certain drug developments, and a press release and corporate presentation filed as exhibits. There are no detailed financial statements or comprehensive financial analysis present. The document primarily serves as a regulatory announcement of recent company events and updates rather than a full financial report or earnings release. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other specific categories.
2023-09-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.